Regenxbio (RGNX) Cost of Revenue (2014 - 2024)

Regenxbio's Cost of Revenue history runs 12 years deep, the most recent figure standing at $5.9 million for Q4 2025.

• In Q4 2025, Cost of Revenue fell 6.17% year-over-year to $5.9 million; the TTM figure through Dec 2025 stood at $20.3 million (down 39.53% YoY), while the FY2025 annual figure was $20.3 million, down 39.53% from the prior year.
• Cost of Revenue for Q4 2025 stood at $5.9 million, up from $5.7 million in the prior quarter.
• The five-year high for Cost of Revenue was $23.1 million in Q4 2021, with the low at $3.4 million in Q1 2025.
• The 5-year median for Cost of Revenue is $10.2 million (2021), against an average of $9.9 million.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue soared 224.0% in 2022, then sank 73.84% in 2023.
• Regenxbio's Cost of Revenue stood at $23.1 million in 2021, then sank by 44.56% to $12.8 million in 2022, then slipped by 12.09% to $11.2 million in 2023, then plunged by 43.78% to $6.3 million in 2024, then retreated by 6.17% to $5.9 million in 2025.
• Business Quant data shows RGNX's Cost of Revenue at $5.9 million in Q4 2025, $5.7 million in Q3 2025, and $5.2 million in Q2 2025.